On March 5, 2025, Denali Therapeutics announced that their DNL343 treatment for ALS did not show a treatment effect on a key biomarker and will discontinue the active treatment extension, following a previous announcement on January 6, 2025, that the study did not meet its primary efficacy endpoint.